User profiles for J. Fellay
Jacques FellayEPFL / CHUV Verified email at epfl.ch Cited by 26145 |
Privacy in the genomic era
… Hubaux, School of Computer and Communication Sciences, Ecole Polytechnique Federale
de Lausanne; email: jeanpierre.hubaux@epfl.ch; J. Fellay, School of Life Sciences, Ecole …
de Lausanne; email: jeanpierre.hubaux@epfl.ch; J. Fellay, School of Life Sciences, Ecole …
[HTML][HTML] Gender medicine and oncology: report and consensus of an ESMO workshop
Background The importance of sex and gender as modulators of disease biology and treatment
outcomes is well known in other disciplines of medicine, such as cardiology, but remains …
outcomes is well known in other disciplines of medicine, such as cardiology, but remains …
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is
the leading cause of cirrhosis in North America 1 . Although the recommended treatment for …
the leading cause of cirrhosis in North America 1 . Although the recommended treatment for …
[HTML][HTML] HIV-1 and human genetic variation
PJ McLaren, J Fellay - Nature Reviews Genetics, 2021 - nature.com
Over the past four decades, research on the natural history of HIV infection has described
how HIV wreaks havoc on human immunity and causes AIDS. HIV host genomic research, …
how HIV wreaks havoc on human immunity and causes AIDS. HIV host genomic research, …
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…
2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus disease 2019 (…
A whole-genome association study of major determinants for host control of HIV-1
Understanding why some people establish and maintain effective control of HIV-1 and
others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-…
others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-…
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B
to be associated with a 2-fold difference in sustained virologic response (SVR) rates to …
to be associated with a 2-fold difference in sustained virologic response (SVR) rates to …
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
… J Fellay, CB Eap, and A Telenti designed the study. C Marzolini and LA Decosterd measured
drug … The report was written by J Fellay and A Telenti, with contributions from all co-authors. …
drug … The report was written by J Fellay and A Telenti, with contributions from all co-authors. …
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and
is an important cause of liver-related morbidity and mortality 1 . The standard of care therapy …
is an important cause of liver-related morbidity and mortality 1 . The standard of care therapy …
[HTML][HTML] Common genetic variation and the control of HIV-1 in humans
To extend the understanding of host genetic determinants of HIV-1 control, we performed a
genome-wide association study in a cohort of 2,554 infected Caucasian subjects. The study …
genome-wide association study in a cohort of 2,554 infected Caucasian subjects. The study …